GlassScriptPhysician profile
Derek M Brickner
NPI 1346405602
$1,660.41
in general payments reported to CMS, 2019-2025
29 companies · $257 in 2025
The $257 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $35.51 · 2021: $273 · 2022: $316 · 2023: $331 · 2024: $229 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $817.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $232.80 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $122.11 | 2021-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $122.04 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $110.20 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.38 | 2019-2024 | Jardiance, Tradjenta |
| Lilly USA, LLC | $105.58 | 2019-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $104.12 | 2019-2024 | Verquvo, Steglatro, Belsomra |
| Abbvie INC. | $73.40 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $68.17 | 2020-2022 | |
| Dexcom, INC. | $61.39 | 2023-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $57.15 | 2020-2024 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $52.33 | 2021-2024 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $45.08 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.22 | 2022 | |
| Phathom Pharmaceuticals, INC. | $38.73 | 2025 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $36.81 | 2021-2023 | Nexplanon |
| Abbott Laboratories | $35.53 | 2021-2023 | Freestyle Libre 2 |
| Teva Pharmaceuticals USA, INC. | $34.14 | 2023 | Austedo, Uzedy |
| Astellas Pharma US INC | $32.48 | 2022-2023 | Veozah |
| Boston Scientific Corporation | $31.52 | 2024 | |
| Mylan Specialty L.P. | $24.32 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.00 | 2019-2021 | |
| Axsome Therapeutics, INC. | $15.31 | 2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $15.04 | 2025 | Jornay Pm |
| Dermira, INC. | $14.99 | 2019 | |
| Medtronic, INC. | $14.51 | 2024 | Minimed 780g |
| Lundbeck LLC | $14.02 | 2023 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $13.69 | 2025 | Rexulti |
| Biogen, INC. | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Brickner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.